Please assess the completion status of the following clinical trial:

Trial Title: Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Patients with neuroblastoma have received standard first-line therapy and been judged to be non-resectable, metastatic, progressive/persistent or recurrent.~2. The GD2 antigen status of the neuroblastoma will be determined for eligibility. Positive expression is defined by GD2 antibody staining results based on immunohistochemistry or flow cytometry analyses.~3. Body weight greater than or equal to 10 kg.~4. Age: ≥1 year and ≤ 14 years of age at the time of enrollment.~5. Life expectancy: at least 8 weeks.~6. Prior Therapy: 1) There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less. 2) Must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. 3) At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic nonmyelosuppressive regimen. 4) At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. 5) At least 1 weeks since any radiation therapy at the time of study entry.~7. Karnofsky/jansky score of 60% or greater.~8. Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent .~9. Pulse Ox greater than or equal to 90% on room air.~10. Liver function: defined as alanine transaminase (ALT) \<3x upper limit of normal (ULN), aspartate aminotransferase (AST) \<3x ULN; serum bilirubin and alkaline phosphatase \<2x ULN.~11. Renal function: Patients must have serum creatinine less than 3 times upper limit of normal.~12. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion).~13. Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable for hematologic toxicity.~14. Patients must have autologous transduced T cells at levels greater than or equal to 2x10e5 cells per kilogram body weight.~15. For all patients enrolled in this study, their parents or legal guardians must sign an informed consent and assent.~EXCLUSION CRITERIA:~1. Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity.~2. Untreated central nervous system (CNS) metastasis:~   Patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible.~3. Previous treatment with other genetically engineered GD2-CAR T cells.~4. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection.~5. Patients who require systemic corticosteroid or other immunosuppressive therapy.~6. Patients previously experienced severe toxicity from cyclophosphamide or fludarabine.~7. Evidence of tumor potentially causing airway obstruction.~8. Inability to comply with protocol requirements.~9. Insufficient CAR T cells availability.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- effectiveness of Anti-GD2 CART (Type: EXPERIMENTAL): Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma

Based on this trial design, predict the completion outcome and termination type (if applicable).